A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Ixmyelocel-T (Primary)
  • Indications Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms REVIVE
  • Sponsors Vericel Corporation
  • Most Recent Events

    • 07 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top